Research Article

Effects of Alendronate Sodium Content on the Interface Strengths of Composite Acrylic Bone Cement

De-Ye Song, Xin-Zhan Mao, Mu-liang Ding, and Jiang-Dong Ni

Department of Orthopaedics, 2nd Xiangya Hospital, Central South University, Changsha, Hunan 410011, China

Correspondence should be addressed to Jiang-Dong Ni; njddoc@126.com

Received 20 November 2014; Revised 15 January 2015; Accepted 21 January 2015

Objective. Aim to study how the content of alendronate affected shear strengths at bone-bone cement-metal interfaces.

Methods. All samples were divided into 6 groups, G0–G5. On the 1st and 60th day after surgery, bone-bone cement interface shear strengths and bone densities were examined. Interface strengths of metal-bone cement specimens were studied before immersion and 4 weeks after immersion.

Results. On the 60th day, bone-bone cement interface shear strengths and bone densities showed significant differences ($P < 0.05$), and compared with G0, G2–G5 values increased significantly ($P < 0.05$), and the peak value was met in G3. Compared with the 1st day, on the 60th postoperative day both factors decreased significantly in G0 and G1 ($P < 0.05$). Four weeks after immersion, with the increasing dose of alendronate, the shear strengths decreased gradually and in G5 decreased significantly ($P < 0.05$). Compared with before immersion, the metal-bone cement interface strengths decreased significantly 4 weeks after immersion ($P < 0.05$). Conclusions. 50–500 mg alendronate in 50 g cement powders could prevent the decrease of shear strengths at bone-bone cement interfaces and had no effect on metal-bone cement interface strengths. While the addition dose was 100 mg, bone cement showed the best strengths.

1. Introduction

With the growing aging population, the number of osteoporotic elderly hip fracture patients has been gradually increasing [1]. Bone cement prosthesis replacement has become a very effective method to treat these fractures [2]. Due to the continual friction between the joint prosthesis, aseptic loosening induced by wear particles has become the main reason of the failure in long-term joint replacement [3]. Therefore, how to prevent bone loss and the aseptic loosening after joint prosthesis replacement has become a research focus.

As a class of synthetic analogs of pyrophosphate, bisphosphonate is a potent new drug to inhibit bone resorption [4]. Experiment researches had shown that the drug could inhibit bone loss after joint prosthesis arthroplasty [5], continuously increasing bone densities around the prostheses [6], inhibiting the release of osteolytic factors [7], inhibiting osteolysis induced by wear particles [8], promoting the proliferation and differentiation of osteoblasts [9], enhancing osteoblast activity, inhibiting apoptosis of osteoblasts [10] and bone absorption of osteoclasts, and accelerating apoptosis of osteoclasts [11]. It is supposed that the drug may be an ideal drug to prevent and cure aseptic loosening after prosthesis replacement.

Oral taking is a major administration of bisphosphonates. If these drugs are taken orally for a long time, they have a lot of side effects, such as low bioavailability, high treatment costs, and upper gastrointestinal ulcers [12, 13]. To avoid these side effects, the topical use added in acrylic bone cement may be a better way of administration. Alendronate is a third generation of bisphosphonate and a regular drug used in the treatment of osteoporosis and osteoporotic fractures. In the form of powder, it has some advantages of being mixed easily in bone cement powders, high temperature resistance and remaining drug efficacy in bone cement, and so forth. Literatures reported that acrylic bone cement compounded with alendronate had a favorable biocompatibility [14], and certain contents of alendronate showed no detrimental effects on the fatigue life of composite acrylic bone cement [15].

Bone-bone cement and metal-bone cement interfaces are common sites of aseptic loosening after bone cement joint
replacement. However, there is no report about whether these interfaces of composite bone cement being affected or not when alendronate is added. To this end, we used composite acrylic bone cement with different dose of alendronate and made the research mentioned above. The aim was to investigate the change of interface strengths, bone densities, and interface microstructure after alendronate was added.

2. Materials and Methods

2.1. Experimental Animals and Materials. Pure alendronate powder (Merck, USA) and Cemex XL bone cement (Tecres SpA, Verona, Italy) were used as received; stainless steel cylinders (diameter 10 mm × length 37 mm), hollow polypropylene tube (inside diameter 16 mm × outside diameter 20 mm × height 20 mm), the axial positioning ring (Figure 1(a)) (inside diameter 10 mm × outside diameter 20 mm × thickness 10 mm), the metal rod positioning system (Figure 1(b)), and the universal tester (type INSTRON 8032) were obtained from Institute of Biological Materials, Central South University. New Zealand rabbits were supplied by the animal Laboratory, the Second Xiang'ya Hospital. The bone density scanner was supplied by the endocrine laboratory of the Second Xiang'ya Hospital. The study design and experimental procedures were approved by our institution’s Animal Care and Use Committee.

2.2. Grouping. According to the amount of alendronate added, all drug samples were divided into 6 groups, G₀–G₅ (i.e., 0, 10, 50, 100, 500, and 1000 mg alendronate were added in 50 g bone cement powder, resp.).

2.3. Preparation of Metal-Bone Cement Interface Strength Specimens. Bone cement was mixed with different dose of alendronate according to the dose regimes above. Then the full reacted mixture was injected into hollow polypropylene tubes, respectively. Stainless steel cylinders with positioning rings were slowly inserted into these tubes. The positioning rings were adjusted to their outside diameter overlapping with the outside diameter of the pipes. After bone cement had solidified, the positioning rings were removed, and bone cement-metal interface specimens were prepared (Figure 1(c)).

2.4. Measurement of Metal-Bone Cement Interface Shear Strengths. Specimens were placed on the INSTRON 8032 universal tester, and ten specimens per group, five specimens before immersion, and five specimens 4 weeks after immersion were tested. The metal cylinders were pushed out at the speed of 5.0 mm/min, and the maximum force launched (F) was measured. The metal-bone cement interface shear strengths (E) were calculated by the following formula and its units were MPa. Consider

\[ E = \frac{F}{\pi \cdot d \cdot h}. \]

In the equation: F stand for metal cylinder’s maximum force launched, in the unit of Newton (N), d for metal cylinder’s diameter (10 mm), and h for the height of metal off the bone cement interface (20 mm).

2.5. Microscopic Observation of Metal-Bone Cement Interfaces. Six specimens examined by push-out test were chosen (one specimen before immersion and one specimen 4 weeks after immersion for G₀, G₃, and G₅). These samples were cut longitudinally into four equal parts by electric saws. One part of samples was coated with gold and these interfaces were observed by electron microscopy.

2.6. Preparation of Bone-Bone Cement Interface Shear Strength Specimens. New Zealand rabbits were operated under intraperitoneal anesthesia (1% sodium pentobarbital, 1.5–2.0 mL/kg). After the success of anesthesia, the surgical area was shaved and cleansed well with 5% benzalkonium bromide and draped the operation area. During the surgery, the rabbits were supplemented with 1% lidocaine as local anaesthetics. An incision about 1.5 cm was made to expose the distal femur by the lateral patellar approach. 3.5 mm drill was used to prepare bone holes and it orientated from the femoral attachment point of the lateral collateral ligament to the femoral medial condyle. When the medial skin of knee was lifted, the incision about 1.0 cm was extended to expose the medial condyle. The wound and bone tunnel were repeatedly washed with hydrogen peroxide and saline, and hemostasis was achieved with fine gauze. Bone cement liquid monomer was mixed with its powders containing different amounts of alendronate. When the reaction was full, the mixture was
filled into a volume of 20 mL injector and injected into the bone tunnels in the bilateral distal femurs. Moderate pressure was applied to both ends of the tunnel until the bone cement solidified. The wound was washed twice and closed layer by layer. Penicillin (800,000 U) was injected by intramuscular injection every day after surgery for 7 days. During the observation period, the rabbits were fed under a standard diet and raised in separate cages.

2.7. Preparation of the Bone-Bone Cement Interface Specimens. Twelve rabbits were assigned to each group. Six rabbits were sacrificed on the 1st day, and the other six rabbits on 60th day after surgery. The lower ends of the femurs, which contained the specimens, were removed. The left specimens were used to test the bone-bone cement interface shear strengths, while the right ones were used to scan bone densities surrounding the interfaces.

2.8. Test of Shear Strength at the Bone-Bone Cement Interfaces. Bilateral femur condyles of the rabbits were trimmed to bone-bone cement interface samples with 9.0 mm lengths with scalp. Then the specimens were loaded on an INSTRON 8032 universal tester, with a loading speed of 5 mm/min. The tester was halted until the load began to decline gradually. The maximum load was recorded, and the interface shear strengths (E), in the unit of MPa, were calculated by the following equation:

\[ E = \frac{F}{\pi \cdot d \cdot l} \]  

(2)

In the equation: \( F \) stand for maximum load force launched, in the unit of Newton (N), \( d \) for bone cement cylinder’s diameter (3.5 mm), and \( l \) for the length of bone-bone cement interface (9.0 mm).

2.9. Bone Densities Surrounding the Bone-Bone Cement Interfaces. Specimens were trimmed to bone-bone cement interface surface with 3.0 mm thickness with scalpel. Then cut unnecessary bone and make these samples of a standard size (length 6.0 mm \( \times \) width 6.0 mm \( \times \) thickness 3.0 mm) and at the same time make sure the bone cement cylinders locate in the center of the specimens. Specimens were scanned using a bone density scanner and the bone densities were calculated by the tester’s software.

2.10. Statistical Analysis. SPSS 13.0 for Windows software was used for the statistical analysis. Each set of data were expressed as mean ± standard deviation (SD) and one-way analysis of variance was performed. If there was a significant difference, pairwise comparison was carried out between groups using Scheffe post hoc test. Paired t-tests were used for the shear strengths and the bone densities at bone-bone cement interface between the 1st day and 60th day after surgery, and metal-bone cement interface strengths between before immersion and 4 weeks after immersion. Test level bilateral \( \alpha = 0.05 \) and \( P < 0.05 \) was considered statistically significant.

Table 1: Shear strengths of bone-bone cement interfaces (MPa) on the 1st day and 60th day after surgery in each group.

| Group | 1st day | 60th day | \( P^* \) |
|-------|---------|----------|-----------|
| G0 | 5.5372 ± 0.2516 | 3.6700 ± 0.1341 | <0.05 |
| G1 | 5.5868 ± 0.1729 | 3.7600 ± 0.1707 | <0.05 |
| G2 | 5.5573 ± 0.2041 | 5.6625 ± 0.2906* | >0.05 |
| G3 | 5.5630 ± 0.2708 | 5.6967 ± 0.2170* | >0.05 |
| G4 | 5.6450 ± 0.2843 | 5.6100 ± 0.2184* | >0.05 |
| G5 | 5.3330 ± 0.1787 | 5.6300 ± 0.1975* | >0.05 |

\( P^* \) indicates one-way analysis of variance (ANOVA); * indicates t-test, \( P < 0.05 \); # indicates Scheffe’s post hoc test, \( P < 0.05 \) compared with G0.

Table 2: Bone densities surrounding the bone-bone cement interfaces (g/cm²) on the 1st day and 60th day after surgery in each group.

| Group | 1st day | 60th day | \( P^* \) |
|-------|---------|----------|-----------|
| G0 | 0.2396 | 0.1356 ± 0.0274 | <0.05 |
| G1 | 0.2455 ± 0.0427 | 0.1313 ± 0.0095 | <0.05 |
| G2 | 0.2512 ± 0.0108 | 0.2509 ± 0.0275* | >0.05 |
| G3 | 0.2525 ± 0.0121 | 0.2584 ± 0.0206* | >0.05 |
| G4 | 0.2546 ± 0.0111 | 0.2554 ± 0.0245* | >0.05 |
| G5 | 0.2546 ± 0.0138 | 0.2512 ± 0.0139* | >0.05 |

\( P^* \) indicates one-way analysis of variance (ANOVA); * indicates t-test, \( P < 0.05 \); # indicates Scheffe’s post hoc test, \( P < 0.05 \) compared with G0.

3. Results

3.1. Shear Strengths of the Bone-Bone Cement Interfaces. Table 1 showed that on the 1st day after surgery, bone-bone cement interface shear strengths showed no significant differences in all groups (\( P > 0.05 \)). However, on the 60th day after surgery, they showed significant differences (\( P < 0.05 \)), and compared with G0, bone-bone cement interface shear strengths in G4 showed no significant differences (\( P > 0.05 \)), but in the other groups their values increased significantly (\( P < 0.05 \)), and the peak value was met in G5. Compared with the 1st postoperative day, on the 60th postoperative day bone-bone cement interface shear strengths significantly decreased in G0 and G1 (\( P < 0.05 \), not in G2 to G5 (\( P > 0.05 \)).

3.2. Bone Densities Surrounding the Bone-Bone Cement Interfaces. Table 2 showed that on the 1st day after surgery, bone densities surrounding bone-bone cement interfaces showed no significant differences in all groups (\( P > 0.05 \)). However, on the 60th day after surgery, they showed significant differences (\( P < 0.05 \)), and compared with G0, bone-bone cement interface shear strengths in G5 showed no significant differences (\( P > 0.05 \)), but in the other groups their values increased significantly (\( P < 0.05 \)), and the peak value was met in G3. Compared with the 1st postoperative day, on the 60th postoperative day bone densities surrounding bone-bone cement interfaces significantly decreased in G0 and G1 (\( P < 0.05 \), not in G2 to G5 (\( P > 0.05 \)).
Figure 2: Electron microscopy of the metal-bone cement interfaces: (a) and (d) before immersion and 4 weeks after immersion in \( G_0 \), respectively; (b) and (e) before immersion and 4 weeks after immersion in \( G_3 \), respectively; and (c) and (f) before immersion and 4 weeks after immersion in \( G_5 \), respectively.

Table 3: Shear strengths of the metal-bone cement interfaces (MPa) before immersion and 4 weeks after immersion in each group.

| Group | Before immersion | 4 weeks after immersion | \( P^\# \) |
|-------|------------------|------------------------|----------|
| \( G_0 \) | 5.746 ± 0.7701 | 4.244 ± 0.0709 | <0.05 |
| \( G_1 \) | 5.668 ± 0.0864 | 4.200 ± 0.0632 | <0.05 |
| \( G_2 \) | 5.652 ± 0.0834 | 4.178 ± 0.0581 | <0.05 |
| \( G_3 \) | 5.598 ± 0.1188 | 4.172 ± 0.0286 | <0.05 |
| \( G_4 \) | 5.564 ± 0.1250 | 4.138 ± 0.0835 | <0.05 |
| \( G_5 \) | 5.534 ± 0.1043 | 3.530 ± 0.0418* | <0.05 |
| \( P^{##} \) | 0.053 | <0.05 |

Note: \(^{##}\) indicates one-way analysis of variance (ANOVA); \(^{\#}\) indicates \( t \)-test, \( P < 0.05 \); \(^{*}\) indicates Scheffé's post hoc test, \( P < 0.05 \) compared with \( G_0 \).

3.3. Shear Strengths of Metal-Bone Cement Interfaces. Table 3 showed that before immersion, metal-bone cement interface strengths in all groups showed no significant difference (\( P > 0.05 \)), while 4 weeks after immersion, with the increasing dose of alendronate, the shear strengths decreased gradually, and in \( G_5 \) the decrease showed significant difference (\( P < 0.05 \)). Compared with that before immersion, the metal-bone cement interface strengths significantly decreased in all groups 4 weeks after immersion (\( P < 0.05 \)).

3.4. Electron Microscopy Observation of the Metal-Bone Cement Interfaces. Figure 2 showed that the porosity of bone cement specimens was similar before immersion, or 4 weeks after immersion in \( G_0 \), \( G_3 \), or \( G_5 \). But compared with before immersion, the porosity in the same group increased obviously 4 weeks after immersion.

4. Discussion

The interfaces between the femoral component and bone cement were known to be a weak area of bone-bone cement prosthesis complex [16]. Previously, Harris and Jasty found that the main mechanism of aseptic loosening on the femoral side was the debonding of the femoral component-bone cement by analyzing the prosthesis removed. Finite element analysis showed that shear stress was a major stress factor for joint prosthesis failure [17]. Interface shear strengths were influenced by a variety of factors, including surface roughness of the femoral stem component, preheating or precoating of the stem component [18], precooling of bone cement monomer, the type of bone cement, the type of prosthesis metal, and the load rate. As a part of this study, we investigated the effects of alendronate on metal-bone cement interface shear strengths. The results showed that before immersion, there is no significant difference in the metal-cement interface strengths in all groups, while 4 weeks after immersion, with the increasing dose of alendronate, the shear strengths decreased gradually, and in group \( G_5 \) the decrease showed significant difference. Meanwhile, electron microscopy showed that no significant difference was found with regard to the interface porosity before immersion or 4 weeks after immersion in groups \( G_0 \), \( G_3 \), and \( G_5 \). These results indicated that the decrease of shear strength of metal-bone cement, was more attributed to decrease of the bone cement bonding capacity than the interface porosity. These studies also found that, compared with that before immersion, 4 weeks after immersion the metal-bone cement interface strengths decreased significantly in the same group. Therefore, it was proposed that the main factor decreasing
bone cement bonding capacity might be related to immersion in saline.

Bone-bone cement interfaces were another common site of aseptic loosening after joint prosthesis replacement. According to published reports, aseptic loosening about approximately 50–79% was found 15 years after total hip arthroplasty for young active patients, and 16% of these patients needed revision arthroplasty [19]. Because of the impossibility of bonding between hydrophobic bone cement and hydrophilic bone tissues, bone cement was used as fillers instead of binders [19]. Instead, interfaces between bone cement and bone tissue become stable fixation by a mechanical intercourse locking. Some studies showed that the shear strengths of bone-bone cement interfaces could be increased by enhancing microlocking between bone cement and bone, and precoating with a layer of an amphiphilic substance on the bone surface. There are many factors that can influence the interface shear strengths, including bone porosity [20], trabecular orientation [20], continuous pressures on the cement [20], preparation of bone surface, and viscosity of bone cement. Moran et al. found that shear strengths of bone-bone cement interfaces were not influenced by gentamicin (0.5 g, 1.0 g, 2.0 g, or 4.0 g) added in 40 g bone cement powders [21]. Moreover, the shear strengths in bone cement were higher than that at bone-bone cement interfaces. Therefore, it is obvious that shear strengths of bone-bone cement interface are a key factor for joint prosthesis service life.

This study found that on the 1st day after surgery shear strengths of bone-bone cement interface in all groups showed no significant difference. However, significant differences were observed on the 60th day after operation. Compared with the 1st day, the interface strengths decreased significantly after 60 days after surgery in G₀ and G₁, but no obvious changes were shown in G₂–G₅. To investigate the reason of shear strengths’ changes, we scanned the bone densities surrounding the bone-bone cement interfaces on the 1st and 60th day after surgery. The results showed that there were similar changes between bone densities and shear strengths at bone-bone cement interfaces. According to the phenomenon above, we inferred that the bone densities might be an important factor to decide the shear strengths at bone-bone cement interfaces. The reason was that bone cement had better mechanical strengths than trabecular bone tissue. Meanwhile, in G₀ and G₁, bone densities had significant reduction after 60 days after operation. It might be related to surgical trauma, thermal damage from bone cement, and activities reduction of rabbits. However, in G₂–G₅, bone densities at bone-bone cement interfaces showed no significant change. This might result from mineralization capacity enhancement of osteoblast and function inhibition of osteoclast, which was caused by the topical release of alendronate and offset of the negative effects on bone densities.

The advantages and disadvantages of this study also deserved discussion: (1) In this study, we used distal femurs of New Zealand rabbits to prepare the bone-bone cement interfaces. Compared with diseased femoral heads used by Moran [21], the advantages included convenience of obtaining specimens, and an increase in sample volume, and avoiding negative impact from structure differences in diseased bone. However, using healthy tissue also had some drawbacks. These specimens obtained were smaller and more difficult to prepare bone-bone cement interfaces. When alive specimens subjects were used, the bleeding at the interfaces could affect the study results. (2) As artificial femoral stem substitute, stainless steel cylinder had different morphology and surface friction coefficient, which resulted in different shear strength values. However, we had already homogenized these factors that might affect the interface strengths in our experiments, therefore the study results were reliable.

In conclusion, these results showed that a certain amount of alendronate in bone cement had a remarkable effect on interface strengths of composite acrylic bone cement and interfacial bone densities. A dose of 50–500 mg alendronate in 50 g bone cement powder could prevent the decrease of interface strengths at bone-bone cement interfaces, and it had a similar effect on bone densities around these interfaces. However, the same doses of alendronate showed no effect on the interface strengths of metal-bone cement interfaces before immersion and 4 weeks after immersion. While the addition dose was 100 mg, bone cement showed the best strengths. The results of this study indicated that alendronate-loaded bone cement could be made, but alendronate amount must be controlled to below a certain level which had no effect on the shear strengths at metal-bone cement-bone interfaces.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This study was supported in part by a grant from the Development and Reform Commission Plan of Hunan Province (2013 no. 1199). The authors would like to extend their appreciation to Dr. Junjie Wang and Dr. Jun Wang for their constructive suggestions.

References

[1] S. R. Cummings and L. J. Melton III, “Epidemiology and outcomes of osteoporotic fractures,” The Lancet, vol. 359, no. 9319, pp. 1761–1767, 2002.
[2] W. H. Harris, “The problem is osteolysis,” Clinical Orthopaedics and Related Research, no. 311, pp. 46–53, 1995.
[3] J. E. Dowd, L. J. Schwendeman, W. Macaulay et al., “Aseptic loosening in uncemented total hip arthroplasty in a canine model,” Clinical Orthopaedics and Related Research, no. 319, pp. 106–121, 1995.
[4] B. Jobke, P. Milovanovic, M. Amling, and B. Busse, “Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients,” Bone, vol. 6, no. 59, pp. 37–43, 2013.
[5] A. Nehme, G. Maalouf, J.-L. Tricoire, G. Giordano, P. Chiron, and J. Puget, “Effect of alendronate on periprosthetic bone loss after cemented primary total hip arthroplasty: a prospective
randomized study,” *Revue de Chirurgie Orthopedique et Reparatrice de l'Appareil Moteur*, vol. 89, no. 7, pp. 593–598, 2003.

[6] J. K. Lee, C. H. Choi, and C.-N. Kang, “Quantitative computed tomography assessment of bone mineral density after 2 years’ oral bisphosphonate treatment in postmenopausal osteoarthritis patients who underwent total knee arthroplasty,” *Journal of International Medical Research*, vol. 41, no. 3, pp. 878–888, 2013.

[7] O. L. Huk, D. J. Zukor, J. Antoniou, and A. Petit, “Effect of pamidronate on the stimulation of macrophage TNF-α release by ultra-high-molecular-weight polyethylene particles: a role for apoptosis,” *Journal of Orthopaedic Research*, vol. 21, no. 1, pp. 81–87, 2003.

[8] C. Trevisan, V. Nava, M. Mattavelli, and C. G. Parra, “Bisphosphonate treatment for osteolysis in total hip arthroplasty. A report of four cases,” *Clinical Cases in Mineral and Bone Metabolism*, vol. 10, no. 1, pp. 61–64, 2013.

[9] G.-I. Im, S. A. Qureshi, J. Kenney, H. E. Rubash, and A. S. Shanbhag, “Osteoblast proliferation and maturation by bisphosphonates,” *Biomaterials*, vol. 25, no. 18, pp. 4105–4115, 2004.

[10] L. I. Plotkin, R. S. Weinstein, A. M. Parfitt, P. K. Roberson, S. C. Manolagas, and T. Bellido, “Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin,” *Journal of Clinical Investigation*, vol. 104, no. 10, pp. 1363–1374, 1999.

[11] M. Kellinsalmi, H. Mönkkönen, J. Mönkkönen et al., “In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts,” *Basic and Clinical Pharmacology and Toxicology*, vol. 97, no. 6, pp. 382–391, 2005.

[12] M. A. Gonzalez-Moles and J. V. Bagan-Sebastian, “Alendronate-related oral mucosa ulcerations,” *Journal of Oral Pathology and Medicine*, vol. 29, no. 10, pp. 514–518, 2000.

[13] P. C. de Groen, D. F. Lubbe, L. J. Hirsch et al., “Esophagitis associated with the use of alendronate,” *New England Journal of Medicine*, vol. 335, no. 14, pp. 1016–1021, 1996.

[14] T. Calvo-Fernández, J. Parra, M. Fernández-Gutiérrez et al., “Biocompatibility of alendronate-loaded acrylic cement for vertebroplasty,” *European Cells and Materials*, vol. 20, pp. 260–273, 2010.

[15] G. Lewis and S. Janna, “Alendronate in bone cement: fatigue life degraded by liquid, not by powder,” *Clinical Orthopaedics and Related Research*, no. 445, pp. 233–238, 2006.

[16] T. P. Harrigan, J. A. Kareh, D. O. O’Connor, D. W. Burke, and W. H. Harris, “A finite element study of the initiation of failure of fixation in cemented femoral total hip components,” *Journal of Orthopaedic Research*, vol. 10, no. 1, pp. 134–144, 1992.

[17] N. Verdonschot and R. Huiskes, “The effects of cement-stem debonding in THA on the long-term failure probability of cement,” *Journal of Biomechanics*, vol. 30, no. 8, pp. 795–802, 1997.

[18] R. T. Müller and N. Schürmann, “Shear strength of the cement metal interface—an experimental study,” *Archives of Orthopaedic and Trauma Surgery*, vol. 119, no. 3-4, pp. 133–138, 1999.

[19] H. J. Erli, R. Marx, O. Paar, F. U. Niethard, M. Weber, and D. C. Wirtz, “Surface pretreatments for medical application of adhesion,” *BioMedical Engineering Online*, vol. 2, article 15, 2003.

[20] J. Graham, M. Ries, and L. Pruitt, “Effect of bone porosity on the mechanical integrity of the bone-cement interface,” *The Journal of Bone and Joint Surgery. American Volume*, vol. 85, no. 10, pp. 1901–1908, 2003.

[21] J. M. Moran, A. S. Greenwald, and M. B. Matejczyk, “Effect of gentamicin on shear and interface strengths of bone cement,” *Clinical Orthopaedics and Related Research*, vol. 141, pp. 96–101, 1979.